CVM

Cel-Sci Corporation

2.67 USD

Last updated Dec 10, 17:36 UTC

Yesterday HIGH

$2.79

Yesterday LOW

$2.62

52w HIGH

$3.33

52w LOW

$1.04

EPS

-0.19

PE

-14.05

Next Earnings

Dec 26, 2023

Overview News Government Trades

Cel-Sci Corporation stock is up 14.1% since 30 days ago. The next earnings date is Dec 26, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 18.52% of the previous 26 December’s closed higher than November.

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for head and neck cancer. Its Ligand Epitope Antigen Presentation System stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Stock Exchange

NYSE MKT

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Denver, United States Of America

Website

cel-sci.com

Lisa Levin

Tue Jul 18, 2023

US Stocks Mixed; Bank of America Tops Q2 Views

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 70 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.20% to 34,655.10 while the NASDAQ fell 0.38% to 14,190.20. The S&P 500, also fell, declining, 0.05% to 4,520.47.
Benzinga Insights

Tue Jul 18, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Lisa Levin

Tue Jul 18, 2023

Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket

Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
Benzinga Newsdesk

Tue Jul 18, 2023

CEL-SCI Prices Public Offering Of 2.5M Common Shares At $2/Share
Benzinga Insights

Mon Jul 17, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Happy Mohamed

Mon Jul 17, 2023

CEL-SCI Announces Proposed Public Offering Of Common Stock; Size Not Disclosed

CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a Phase 3 cancer immunotherapy company,today announced that it intends to offer to sell shares of its common stock in an underwritten
Happy Mohamed

Fri Jul 14, 2023

CEL-SCI Concludes Meeting With U.S. FDA Concerning Multikine's Approval For Head & Neck Cancer

FDA acknowledges the great need for improved treatments for head and neck cancer, particularly the locally advanced oral cavity that CEL-SCI is targeting and is open to a close collaboration with CEL-SCI to help
richadhand@benzinga.com

Wed Jul 12, 2023

EF Hutton Reiterates Buy on CEL-SCI, Maintains $10 Price Target

EF Hutton analyst Tony Butler reiterates CEL-SCI (AMEX:CVM) with a Buy and maintains $10 price target.
Benzinga Newsdesk

Tue Jul 11, 2023

CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy And Points To Potential For Combination With Checkpoint Inhibitors For Head And Neck Cancer

Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors which most often show longer survival in a proportion of
Happy Mohamed

Tue May 16, 2023

Watching CEL-SCI; Zacks Small-Cap Research Sets $11 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_05162023_CVM_Vandermosten.pdf